Hostname: page-component-76fb5796d-zzh7m Total loading time: 0 Render date: 2024-04-26T17:43:11.185Z Has data issue: false hasContentIssue false
  • English
  • Français

Change in psychiatrists’ attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia

Published online by Cambridge University Press:  16 April 2020

J. Bobes ,
A.A. Alegría ,
M.D. Saiz-Gonzalez ,
I. Barber ,
J.L. Pérez  and
J. Saiz-Ruiz
J. Bobes*
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (Cibersam), Psychiatry Department, University of Oviedo, Julián Clavería, 6, 33006Oviedo (Asturias), Spain
A.A. Alegría
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (Cibersam), Ramon y Cajal University Hospital, Psychiatry Department, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Carretera Colmenar Viejo, Km 9’100, 28034Madrid, Spain New York State Psychiatric Institute, 1051 Riverside Drive, 10032 NY, New York, USA
M.D. Saiz-Gonzalez
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (Cibersam), Clinic San Carlos University Hospital, Psychiatry Department, Complutense University, Avda. Profesor Laguna, s/n 28040, Madrid, Spain
I. Barber
Affiliation:
Otsuka Pharmaceutical, S.A. Spain, Avda Diagonal, 615, 9 E., 08028Barcelona, Spain
J.L. Pérez
Affiliation:
Bristol Myers Squibb, Medical Department, C/ Almansa, 101, BMS building, 28040Madrid, Spain
J. Saiz-Ruiz
Affiliation:
Centro de Investigación Biomédica en Red de Salud Mental (Cibersam), Ramon y Cajal University Hospital, Psychiatry Department, University of Alcala, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Carretera Colmenar Viejo, Km 9’100, 28034Madrid, Spain
*
*Corresponding author. Tel.: +34 98 5103553; fax: +34 98 5103553 E-mail address: bobes@uniovi.es (J. Bobes).
Get access

Abstract

Purpose

To evaluate the impact of the “Spanish Consensus on Physical Health in Patients with Schizophrenia” on psychiatrists’ evaluations of the physical health of patients with schizophrenia.

Method

Epidemiological, non-interventional, national, multicentre study, with two retrospective, cross-sectional data collection stages in which 229 psychiatrists evaluated 1193 clinical records of patients with schizophrenia (ICD-10) seen in January and September of 2007.

Results

Mean age of the patients was 39.7 ± 11.6 years, 65.5% were men, diagnosed for schizophrenia 14.0 ± 10.3 years ago. Forty percent of the patients suffer from a concomitant disease, the most prevalent being hypercholesterolemia (46.3%), hypertriglyceridaemia (33.5%) and arterial hypertension (26.0%). The difference in the number of patients who had all the physical measurements taken between the two cross-sectional evaluations was 13.8% (CI: 11.8%, 15.7%). The differences for each parameter were: weight 13.7% (CI: 11.7%, 15.6%), BMI 13.58% (CI: 11.6%, 15.5%), waist circumference 14.0% (CI: 12.0%, 15.39%), lipid profile 2.9% (CI: 1.9%, 3.9%) and glycaemia 2.6% (CI: 1.7%, 3.5%).

Conclusions

These results imply that the dissemination of the “Consensus on Physical Health in Schizophrenia Patients”, and possibly other actions, has made psychiatrists more aware of an integral approach to patients with schizophrenia, promoting increased monitoring of the physical health of these patients.

Keywords

SchizophreniaPhysical healthConsensusComorbidities
Type
Original article
Information
European Psychiatry , Volume 26 , Issue 5 , August 2011 , pp. 305 - 312
Copyright
Copyright © Elsevier Masson SAS 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Diabetes Association, American Psychiatric Association, American Asociation of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 496–502Google Scholar
Bobes, J.Arango, C.Aranda, P.Carmena, R.Garcia-Garcia, M.Rejas, J.Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007; 90: 162–173CrossRefGoogle ScholarPubMed
Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010 Mar 8. [Epub ahead of print].CrossRefGoogle Scholar
Brown, S.Inskip, H.Barraclough, B.Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212–217CrossRefGoogle ScholarPubMed
Cohn, T.Prud’homme, D.Streiner, D.Kameh, H.Remington, G.Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004; 49: 753–760CrossRefGoogle ScholarPubMed
De Hert, M.Dekker, J.M.Wood, D.Kahl, K.G.Holt, R.I.G.Möller, J.Cardiovascular disease and diabetes in people with severe mental illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24(6): 412–424[Epub 2009 Aug 13]CrossRefGoogle Scholar
De Hert, M.Dekker, J.M.Wood, D.Kahl, K.G.Möller, H.J.Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave. Declaración de la posición de la Sociedad Psiquiátrica Europea (EPA), respaldada por la Asociación Europea para el Estudio de la Diabetes (EASD) y la Sociedad Europea de Cardiología (ESC). Rev Psiquiatr Salud Ment 2009; 2(1): 49–59Google Scholar
De Hert, M.Schreurs, V.Vancampfort, D.Van Winkel, R.Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8(1): 15–22CrossRefGoogle ScholarPubMed
De Hert, M.Wampers, M.Van Eyck, D.Peuskens, J.Franic, T.Vidovic, D., et al.Prevalence of HIV and hepatitis C infection among patients with schizophrenia. Schizophr Res 2009; 108(1–3): 307–308[Epub 2008 Dec 17]CrossRefGoogle ScholarPubMed
Enger, C.Weatherby, L.Reynolds, R.F.Glasser, D.B.Walker, A.M.Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004; 192: 19–27CrossRefGoogle ScholarPubMed
George, T.P.Vessicchio, J.C.Termine, A.Bregartner, T.A.Feingold, A.Rounsaville, B.J., et al.A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002; 52: 53–61CrossRefGoogle Scholar
Fleischhacker, W.W.Cetkovich-Bakmas, M.De Hert, M.Hennekens, C.H.Lambert, M.Leucht, S., et al.Comorbid somatic illnesses in patients with severe mental disorders: clinical policy, and research challenges. J Clin Psychiatry 2008; 69: 514–519CrossRefGoogle ScholarPubMed
Goff, D.C.Sullivan, L.M.McEvoy, J.P.Meyer, J.M.Nasrallah, H.A.Daumit, G.L., et al.A comparison of 10-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80: 45–53CrossRefGoogle Scholar
Haupt, D.W.Rosenblatt, L.C.Kim, E.Baker, R.A.Whitehead, R.Newcomer, J.W.Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166: 345–353CrossRefGoogle ScholarPubMed
Hennekens, C.H.Hennekens, A.R.Hollar, D.Casey, D.E.Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 111511–111521CrossRefGoogle ScholarPubMed
Kisely, S.Campbell, L.A.Wang, Y.Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry 2009; 195: 545–550CrossRefGoogle ScholarPubMed
Lambert, T.J.Newcomer, J.W.Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009; 190: S39–42CrossRefGoogle ScholarPubMed
Laursen, T.M.Munk-Olsen, T.Agerbo, E.Gasse, C.Mortensen, P.B.Somatic hospital contacts, invasive cardiac procedure, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 2009; 66: 713–720CrossRefGoogle Scholar
Marder, S.R.Essock, S.M.Miller, A.L.Buchanan, R.W.Casey, D.E.Davis, J.M., et al.Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–1349CrossRefGoogle ScholarPubMed
McEvoy, J.P.Meyer, J.M.Goff, D.C.Nasrallah, H.A.Davis, S.M.Sullivan, L., et al.Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32CrossRefGoogle ScholarPubMed
McGrath, J.Saha, S.Welham, J.El Saadi, O.MacCauley, C.Chant, D.A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2: 13CrossRefGoogle ScholarPubMed
Meyer, J.M.Davis, V.G.Goff, D.C.McEvoy, J.P.Nasrallah, H.A.Davis, S.M., et al.Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res 2008; 101: 273–286CrossRefGoogle ScholarPubMed
Meyer, J.M.Koro, C.E.The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17CrossRefGoogle ScholarPubMed
Meyer, J.M.Stahl, S.M.The metabolic syndrome and schizofrenia. Acta Psychiatr Scand 2009; 119(1): 4–14CrossRefGoogle Scholar
Morrato, E.H.Druss, B.Hartung, D.M.Valuck, R.J.Allen, R.Campagna, E., et al.Metabolic testing ratesin 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67(1): 17–24CrossRefGoogle Scholar
Nasrallah, H.A.An overview of common medical comorbidities in patients with schizophrenia. J Clin Psychiatry 2005; 66(Suppl. 6): 3–4Google ScholarPubMed
Nasrallah, H.A.Meyer, J.M.Goff, D.C.McEvoy, J.P.Devis, S.M.Stroup, T.S., et al.Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data form the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15–22CrossRefGoogle Scholar
Newcomer, J.W.Haupt, D.W.The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51: 480–491CrossRefGoogle ScholarPubMed
Newcomer, J.W.Hennekens, C.H.Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298: 1794–1796CrossRefGoogle ScholarPubMed
Nordestgaard, B.G.Benn, M.Schnohr, P.Tybjaerg-Hansen, A.Non fasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308CrossRefGoogle Scholar
Saiz Ruiz, J.Bobes Garcia, J.Vallejo Ruiloba, J.Giner Ubago, J.Garcia-Portilla Gonzalez, M.P.Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. Actas Esp Psiquiatr 2008; 36: 251–264Google ScholarPubMed
Saiz Ruiz J, Saiz Gonzalez MD, Alegría AA, Mena E, Luque J, Bobes J. Impact of the Spanish Consensus on Physical Health of Patients with Schizophrenia. Rev Psiquiatr Salud Ment 2010 (In press).CrossRefGoogle Scholar
Waterreus, A.J.Laugharne, J.D.Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009; 190: 185–189CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.